# Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2021

- Company: [Creative Medical Technology Holdings, Inc.](/companies/celz.md) (CIK 1187953)
- Form: 10-Q
- Filed: 2021-05-17
- Accepted by EDGAR: May 17, 2021, 16:45 ET
- Period: 2021-03-31
- Accession: 0001477932-21-003351
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1187953/000147793221003351/celz_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1187953/000147793221003351/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-01-01 to 2021-03-31 | $0 | us-gaap:Revenues |
| Cost of revenue | 3 months, 2021-01-01 to 2021-03-31 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2021-01-01 to 2021-03-31 | $0 | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2021-01-01 to 2021-03-31 | $280.9k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-01-01 to 2021-03-31 | −$303.9k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-01-01 to 2021-03-31 | $336.1k | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-01-01 to 2021-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-01-01 to 2021-03-31 | $27.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-01-01 to 2021-03-31 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted shares (weighted) | 3 months, 2021-01-01 to 2021-03-31 | 1,244,529,602 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2021-01-01 to 2021-03-31 | −$441.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2021-03-31 | $275.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-03-31 | $275.1k | us-gaap:AssetsCurrent |
| Total assets | at 2021-03-31 | $871.9k | us-gaap:Assets |
| Current liabilities | at 2021-03-31 | $3.3m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2021-03-31 | $662.8k | us-gaap:LongTermDebt |
| Shareholders' equity | at 2021-03-31 | −$2.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 15,969 characters.

*Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2020, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.*

### Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

18

#### Table of Contents

### Overview

Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments. We were incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, we completed a reverse merger transaction under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became our wholly-owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became our principal stockholder. In connection with this merger, we changed our name to Creative Medical Technologies Holdings, Inc. to reflect our current business.

CMT was originally created as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain and liver disease using various types of stem cells through our ImmCelz, Inc., AmnioStem LLC and StemSpine, LLC subsidiaries. However, neither ImmCelz LLC, AmnioStem LLC nor StemSpine LLC have commenced commercial activities.

We currently conduct substantially all of our commercial operations through CMT. CMT markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at 14 locations in the United States and Europe.

In 2020, we formed ImmCelz, Inc., a wholly owned subsidiary of CMT. Through our ImmCelz Inc. subsidiary, we began exploring the development of treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties that may be suitable for the treatment of stroke victims. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

We are currently primarily focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the Unites States, Europe and South America, commercializing our StemSpine® treatment for lower back pain and filing an Innovative New Drug (IND) application to the FDA utilizing our ImmCelz technology platform to treat stroke. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products that utilize our proprietary intellectual property.

Our principal executive offices are located at 211 E Osborn Road, Phoenix, AZ 85012.

During the first three-months of 2021, we issued $157,150 in convertible notes with net proceeds of $134,640 to accredited investors.

During the three-month period ending March 31, 2021, we incurred interest expense of $61,354 arising from the third-party notes of $662,792.

19

#### Table of Contents

#### Plan of Operations

We commenced marketing disposable stem cell concentration kits for the CaverStem® erectile dysfunction treatment in the fourth quarter of 2017 and the FemCelz® female sexual dysfunction treatment in March of 2019. The Company also announced the commercialization of the StemSpine procedure for lower back pain in the fourth quarter of 2019. We also continued filed an Innovative New Drug (IND) application for the ImmCelz™ product to treat stroke. We have commenced physician recruitment to build a 100-patient treatment registry to support our StemSpine® commercialization. For the next 12 months our plan of operations is to continue to expand the market for the CaverStem® and FemCelz® procedures, build the StemSpine patient registry, and coordinate with the FDA to authorize the commencement of the ImmCelz Phase I trial. As of March 31, 2021, we had approximately $275,000 cash on hand. With an estimated monthly cash burn rate of approximately $100,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least June 2021. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of disposable stem cell concentration kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales efforts. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

### Results of Operations – For the Three-month Period Ended March 31, 2021 and 2020

***Gross Revenue.*** We generated no gross revenue for the three-month period ended March 31, 2021, in comparison with $42,500 for the comparable quarter a year ago. The decrease of $42,500 or 100% reflects the ongoing negative impact of the COVID-19 pandemic.

***Cost of Goods Sold***. We generated no cost of goods sold for the three-month period ended March 31, 2021, in comparison with $14,196 for the comparable quarter a year ago. The decrease of $14,196 or 100% is due to the lack of sales in the quarter.

***Gross Profit/(Loss)***. We generated no gross profit for the three-month period ended March 31, 2021, in comparison with $27,904 for the comparable quarter a year ago. The decrease of $27,904 or 100% is due to the lack of sales in the quarter.

***General and Administrative Expenses.*** General and administrative expenses for the three-month period ended March 31, 2021, totaled $280,293 in comparison with $346,168, for the comparable quarter a year ago. The decrease of $65,245 or 19% is primarily due to a decrease of $20,131 in marketing, $18,336 in legal and $21,431 in accounting expenses.

***Amortization Expenses.*** Amortization expenses for the three-month period ended March 31, 2021, totaled $23,021 in comparison with $16,772, for the comparable quarter a year ago. The increase of $6,249 or 37% is due to the added amortization of the $250,000 Jadi Cell asset.

***Research and Development Expenses.*** There were no research and development expenses for the three-month period ended March 31, 2021, and for the comparable quarter a year ago.

***Other Income / Expense.*** Other income for the three-month period ended March 31, 2021, totaled $28,139,963 in comparison with $4,077,516, for the comparable quarter a year ago. The increased income of $24,062,447, or 590% is primarily due to a gain in the fair value of derivative liabilities of $28,476,039, compared to a gain of $4,400,739 for the comparable quarter a year ago.

***Net Income/Loss.*** For the reasons stated above, our net income for the three-month period ended March 31, 2021, totaled $27,836,019 in comparison to $3,742,480, for the comparable quarter a year ago.

### Liquidity and Capital Resources

Our principal source of liquidity has been funds received from the sale of our common and preferred stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by equity investments, funds to be loaned to us by third parties and revenues generated from our Caverstem® ED and FemCelz® vaginal rejuvenation procedures. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.

20

#### Table of Contents

Our only commitments for expenditures relate to general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED and vaginal rejuvenation treatments, building the StemSpine patient registry and initiating the ImmCelz Phase I clinical trial.

For the next 12 months our plan of operations is to market our disposable kits, partner with leading physicians to build the StemSpine patient registry and initiate the ImmCelz Phase I clinical trial. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

### Cash Flows

***Net Cash used in Operating Activities.*** We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $441,518 for the three-month period ended March 31, 2021 in comparison to $195,321 for the comparable period a year ago, a decrease of $246,197 or 126%. The increase in cash used in operations was primarily related to a $212,963 increase in payments owed to CMH and a $60,678 decrease in accounts payable.

***Net Cash used in Investing Activities.*** There was no cash used in investing activities in the three-month period ended March 31, 2021 and March 31, 2020, respectively.

***Net Cash From Financing Activities.*** In the three-month period ended March 31, 2021, we raised $618,640 through the issuance of convertible debt, preferred stock and a related party advance. In the three-month period ended March 31, 2020, we raised $145,000 through the issuance of convertible debt. The $473,640 or 327% increase in cash flows from financing activities were primarily related to the proceeds from the sale of preferred stock.

### Basis of Presentation / Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2021, the Company had $275,000 of available cash and a working capital deficit of $3,039,315. For the three-month period ended March 31, 2021, the Company had no revenue, $303,944 in operating loss and used net cash for operating activities of $441,518. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

21

#### Table of Contents

## Controls and procedures

As filed, 1,628 characters.

### Evaluation of disclosure controls and procedures

As required by Rule 13a-15 under the Exchange Act, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2021.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

### Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

22

#### Table of Contents

Filed May 17, 2021.
Source: SEC EDGAR, the filing index for accession 0001477932-21-003351. Last ingested by Listed: Nov 14, 2026, 19:08 ET. No prices; not investment advice.
